Market & opportunity

Demand is exploding.
Supply is stuck.

Recognition of neurodevelopmental conditions is rising sharply across the UK. NHS pathways are saturated. Independent specialist centres are scaling to fill the gap — but doing so on tooling that wasn’t designed for them.

1 in 7
children in the UK are neurodivergent
4+ yrs
average NHS wait for autism assessment
£1.9M
lifetime cost of undiagnosed autism per person
300+
independent UK paediatric specialist centres
Commercial Trajectory

A two-engine business: run the centre, license the platform.

The flagship centre will validate the clinical model and underwrite the platform’s evolution. The platform itself is engineered for dedicated deployment — every install is isolated, compliance-clean, and hosted either on the partner’s own hardware or on a dedicated managed VPS.

Investor enquiries open
1
2026
Planning phase — clinical model design, governance planning, site feasibility, funding assumptions, and delivery sequencing; no centre implementation yet
2
2027
Preparation phase — centre setup, recruitment planning, operational design, and controlled platform validation
3
2028
Controlled pilot — platform and clinical workflows refined through a small flagship-centre caseload
4
2029
Licensing hardening, partner onboarding tooling, and first external deployments
5
2030+
Multi-site licensee rollout across UK independent centres and SEND-aligned services, with international expansion beyond
The business

Two engines.
One thesis.

Each engine reinforces the other. The centre proves the clinical model and produces revenue. The platform extends that model to other operators and produces recurring licence revenue.

Engine one — the centre

A flagship paediatric neurodevelopmental centre offering consultant-led assessment and multidisciplinary therapy. Validates the clinical model in real-world use; generates clinical revenue from day one.

Engine two — the platform

Nexus CMS, the proprietary clinical management platform built to run that centre. Licensed under dedicated-instance terms to other independent centres, multi-site networks, and SEND-aligned services.

Reinforcing dynamic

Clinical learnings improve the platform. Platform fees fund clinical operations and platform R&D. Each licensee strengthens the moat — clinical, regulatory, and architectural.

Defensible category

We are not building a generic EHR. We are building the category-defining platform for paediatric neurodevelopmental services — with the clinical credibility, the regulatory posture, and the operational depth others cannot replicate quickly.

Traction

Where we are today.

A snapshot of the planning phase in 2026.

Platform built

Nexus CMS is engineered, integrated, and tested. Twenty-five-plus modules covering the full neurodevelopmental pathway — referral through to billing.

Planning phase underway

2026 is focused on planning the clinical model, governance, site feasibility, funding assumptions, and delivery sequence before centre implementation begins.

Commercial planning

Licensing pricing, deployment options, partner onboarding programme, and service-level commitments are being shaped ahead of implementation preparation.

Compliance posture

GDPR, ICO registration, audit infrastructure, security architecture — all in place. Partner organisations can inherit a defensible posture from day one.

Pipeline forming

Inbound interest from independent centres and SEND-aligned operators. Partner conversations active for later-stage onboarding.

Roadmap

A clear staged plan: planning in 2026, preparation in 2027, controlled pilot in 2028, first deployments in 2029, and multi-site rollout from 2030.

Where investment goes

Capital deployed against a clear plan.

A focused use of funds across three categories — no scope creep.

Clinical operations

Bringing the flagship centre fully online. Clinical leadership, multidisciplinary team, and the operational footprint to validate the model at scale.

Platform hardening

Production-grade hardening of the platform: scale, security, partner provisioning tooling, and the engineering capacity to support multiple licensee instances.

Partner go-to-market

A small, focused commercial team to convert the pipeline of independent centres and SEND-aligned services through 2028 and 2029.

Investor contact

Open to early conversations.

We share a full investor brief, financial model, and platform walk-through with qualified investors under NDA. The fastest route is a 30-minute introductory call.